Modified Release Studies on the New Antitubercular Compound (1,1’-[4,4’-[Tricyclo[3.3.1.3.3,7]Decane-1,3-Diyl]Bis(Phenoxyethyl)]Dipyrrolidine, Bis-Hydrochloride Salt from Solid Pharmaceutical Formulations.

M. Vlachou*, A. Siamidi, P. Ladia, K. Anastasiou, I. Papanastasiou

The modified release of a new, potent antitubercular agent (compound 1), from tablets and hard gelatin capsules, into gastrointestinal-like fluids, was probed. Albeit its high lipophilicity, compared to its congeneric derivative, SQ109, the dissolution profile of 1 was found to be in alignment with the release characteristics necessary for antitubercular action (relatively fast initial release followed by a gradient). The excipients used to achieve this dissolution pattern were combinations of sodium alginate, lactose monohydrate, and polyvinylpyrrolidone (PVP).